MSB's share price was cut in half on August 4th by the announcement that they needed to do more work in regards their FDA resubmission 05sb7mjzh4lq3w.pdf (asx.com.au)

Since then, they have been working toward approval of their graft vs host disease treatment but need more cash.

Trading halt today for a cap raise, rumoured to be at 30c, a steep discount to last traded price of 40.5c. This is because it is a massive capital raise and will likely anchor the share price to the raise price for a while to come.

They seemed so close to approval but new drug development is full of risks like this, even for good candidates.

Should be good buying around, or even under 30c. One to stick in the bottom drawer because it will re-rate strongly on favourable news.